Literature DB >> 34629707

Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data.

Janesh Lakhoo1, Thomas H Perez1, Anthony J Borgmann1, Daniel B Brown1.   

Abstract

Historically, outcomes reporting for radioembolization with yttrium-90 ( 90 Y) of hepatocellular carcinoma has included patients across the range of Barcelona Clinic Liver Cancer (BCLC) stages. With the potential for curative radiation segmentectomy for BCLC 0/A patients and evolution of systemic therapy for BCLC C patients, focused review by group is of increasing interest. In this review, we report on efficacy of 90 Y in patients with intermediate (BCLC B) and advanced (BCLC C) hepatocellular carcinoma as well as expected toxicities. Additionally, we review existing trials comparing 90 Y to transarterial chemoembolization and systemic treatments in these patient groups and outline future studies. Thieme. All rights reserved.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer; chemoembolization; hepatocellular carcinoma; interventional radiology; radioembolization

Year:  2021        PMID： 34629707      PMCID： PMC8497091          DOI： 10.1055/s-0041-1733903

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN： 0739-9529            Impact factor:   1.780


  29 in total

Review 1.  Tolerance of normal tissue to therapeutic irradiation.

Authors:  B Emami; J Lyman; A Brown; L Coia; M Goitein; J E Munzenrider; B Shank; L J Solin; M Wesson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-05-15       Impact factor: 7.038

2.  Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.

Authors:  Carole Allimant; Marilyne Kafrouni; Julien Delicque; Diana Ilonca; Christophe Cassinotto; Eric Assenat; Jose Ursic-Bedoya; Georges-Philippe Pageaux; Denis Mariano-Goulart; Serge Aho; Boris Guiu
Journal:  J Vasc Interv Radiol       Date:  2018-09-11       Impact factor: 3.464

Review 3.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

4.  Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments.

Authors:  Riad Salem; Frank H Miller; Vahid Yaghmai; Robert J Lewandowski
Journal:  J Hepatol       Date:  2013-01-24       Impact factor: 25.083

5.  Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.

Authors:  Mercedes Iñarrairaegui; Kenneth G Thurston; Jose I Bilbao; Delia D'Avola; Macarena Rodriguez; Javier Arbizu; Antonio Martinez-Cuesta; Bruno Sangro
Journal:  J Vasc Interv Radiol       Date:  2010-07-03       Impact factor: 3.464

6.  Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach.

Authors:  Ricarda Seidensticker; Max Seidensticker; Robert Damm; Konrad Mohnike; Kerstin Schütte; Peter Malfertheiner; Mark Van Buskirk; Maciej Pech; Holger Amthauer; Jens Ricke
Journal:  Cardiovasc Intervent Radiol       Date:  2011-10-26       Impact factor: 2.740

7.  Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.

Authors:  Rehan Ali; Ahmed Gabr; Nadine Abouchaleh; Ali Al Asadi; Ronald A Mora; Laura Kulik; Michael Abecassis; Ahsun Riaz; Riad Salem; Robert J Lewandowski
Journal:  Cardiovasc Intervent Radiol       Date:  2017-09-06       Impact factor: 2.740

8.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

9.  Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study.

Authors:  Parvez S Mantry; Ashwini Mehta; Bahar Madani; Alejandro Mejia; Islam Shahin
Journal:  J Gastrointest Oncol       Date:  2017-10

10.  Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry.

Authors:  Daniel Brown; Henry Krebs; Jayson Brower; Ryan O'Hara; Eric Wang; Kirubahara Vaheesan; Liping Du; Lea Matsuoka; Donna D'Souza; Daniel Y Sze; Jafar Golzarian; Ripal Gandhi; Andrew Kennedy
Journal:  J Gastrointest Oncol       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.